核桃油和神经酸对抗氧化活性和认知障碍的协同作用
Rui Wang1, Chao Jiang2, Jing Yi Zheng2
1College of Food Science and Engineering, Northwest University, Xi'an, Shaanxi, China.
Journal of food science
|August 21, 2025
概括
核桃油与神经酸的结合显示出增强的抗氧化和认知效益. 这种组合有效地改善了小鼠的认知障碍,减少了氧化应激和脑损伤.
科学领域:
- 神经科学
- 生物化学
- 营养科学
背景情况:
- 认知障碍是与氧化压力相关的日益严重的公共卫生问题.
- 核桃油 (WO) 和神经酸 (NA) 已被认为具有潜在的CI治疗特性.
研究的目的:
- 研究核桃油与神经酸 (WONA) 联合对抗氧化活性和认知功能的协同作用.
- 在CI小鼠模型中评估WONA在改善氧化应激和脑损伤方面的有效性.
主要方法:
- 在H2O2诱导的PC12细胞中使用DPPH激素清除试验评估抗氧化活性.
- 测量了细胞活力,甲酸 (MDA),超氧化脱氧酶 (SOD) 和谷过氧酶 (GSH-Px) 的水平.
- 给D- 银糖诱导的CI小鼠服用WONA,以评估大脑损伤,氧化应激,神经递质平衡和炎症因素.
主要成果:
- 与单个成分相比,WONA表现出更高的DPPH激素清除活性.
- WONA显著提高了细胞活力和抗氧化酶活性 (SOD,GSH- Px),同时降低了PC12细胞中的MDA水平.
- 在CI小鼠中,WONA有效缓解脑损伤,优于单独的WO和NA治疗.
结论:
- 同时使用核桃油和神经酸具有协同作用,增强抗氧化能力和改善认知障碍.
- 作为一种用于治疗认知障碍的新功能食品成分或食补充剂,WONA具有潜力.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Anxiolytic Drugs: Overview
483
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
483
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K


